BRAF inhibitors such as dabrafenib, encorafenib, and vemurafenib focus on melanoma and NSCLC with BRAF mutations [97], while Bruton tyrosine kinase inhibitors such as acalabrutinib and ibrutinib are used for mantle cell lymphoma and chronic lymphocytic leukemia, among others [98]. Here, BRAF is linked to non-small cell lung carcinoma.